UBS initiated coverage of Inventiva (IVA) with a Neutral rating and $3 price target The firm thinks the company’s pan-PPAR agonist lanifibranor, currently in Phase 3 for metabolic dysfunction-associated steatohepatitis with fibrosis stage 2 or 3, has shown “promising” Phase 2 data and as an oral could take a piece of the large MASH market. However, with Phase 3 data expected in the second half of 2026, UBS sees the next two years as an execution period for Inventiva.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVA:
- Inventiva’s Strategic Moves at Upcoming General Meeting
- Inventiva Gains Positive Nod for Lanifibranor Trial
- Inventiva announces DMC recommendation to continue NATiV3 trial as is
- Inventiva’s 2024 Interim Financial Highlights and Prospects
- Inventiva price target lowered to $13 from $14 at H.C. Wainwright